Krensavage Asset Management LLC Cuts Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Krensavage Asset Management LLC cut its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 75.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 100,332 shares of the biopharmaceutical company's stock after selling 314,352 shares during the quarter. Vanda Pharmaceuticals makes up about 0.3% of Krensavage Asset Management LLC's portfolio, making the stock its 10th largest position. Krensavage Asset Management LLC owned approximately 0.17% of Vanda Pharmaceuticals worth $481,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Quantinno Capital Management LP purchased a new position in Vanda Pharmaceuticals during the 4th quarter worth $48,000. XTX Topco Ltd purchased a new stake in Vanda Pharmaceuticals during the fourth quarter valued at about $69,000. Zacks Investment Management purchased a new position in Vanda Pharmaceuticals in the 4th quarter worth $74,000. ProShare Advisors LLC lifted its stake in shares of Vanda Pharmaceuticals by 32.4% in the 4th quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company's stock valued at $90,000 after acquiring an additional 4,599 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in Vanda Pharmaceuticals by 17.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company's stock worth $107,000 after acquiring an additional 3,370 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a "hold" rating for the company. HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $13.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 14th.

Insider Activity

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of Vanda Pharmaceuticals stock in a transaction on Tuesday, February 25th. The shares were acquired at an average price of $4.46 per share, for a total transaction of $44,600.00. Following the completion of the purchase, the chief executive officer now directly owns 2,331,730 shares in the company, valued at approximately $10,399,515.80. This trade represents a 0.43% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders have bought 52,000 shares of company stock valued at $235,580. 10.00% of the stock is currently owned by company insiders.

Vanda Pharmaceuticals Stock Up 3.6%

Vanda Pharmaceuticals stock opened at $4.31 on Tuesday. The firm's fifty day moving average is $4.42 and its 200 day moving average is $4.63. Vanda Pharmaceuticals Inc. has a 52-week low of $3.81 and a 52-week high of $6.75. The company has a market cap of $254.01 million, a price-to-earnings ratio of -13.47 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.05. The firm had revenue of $50.04 million for the quarter, compared to the consensus estimate of $45.13 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. On average, equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.